Bio-Techne Corp.
(NASDAQ : TECH)

( )
TECH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.28%334.840.0%$4823.21m
BNTXBioNTech SE 5.41%261.090.0%$769.86m
NVAXNovavax, Inc. 2.66%166.2579.4%$734.23m
AMGNAmgen, Inc. -2.27%203.131.4%$562.61m
SNSSSunesis Pharmaceuticals, Inc. -3.25%6.260.7%$437.60m
GILDGilead Sciences, Inc. -2.56%65.901.0%$415.54m
REGNRegeneron Pharmaceuticals, Inc. -1.76%543.482.7%$401.78m
ILMNIllumina, Inc. 0.15%410.533.3%$393.44m
CCXIChemoCentryx, Inc. -5.92%32.432.9%$364.70m
XLRNAcceleron Pharma, Inc. 0.04%173.005.3%$345.57m
VRTXVertex Pharmaceuticals, Inc. -0.53%180.801.9%$258.21m
BIIBBiogen, Inc. -4.08%269.731.7%$233.47m
OCGNOcugen, Inc. -4.62%8.260.0%$170.13m
XENEXenon Pharmaceuticals, Inc. -8.73%30.720.4%$162.62m
CRSPCRISPR Therapeutics AG -0.81%96.210.6%$151.63m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.